<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEROPENEM</span><br/>(mer-o'pe-nem)<br/><span class="topboxtradename">Merrem<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">carbapenem antibiotic</span><br/><b>Prototype: </b>Imipenem<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 1 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Broad-spectrum carbapenem antibiotic that inhibits the cell wall synthesis of gram-positive and gram-negative bacteria by
         its strong affinity for penicillin-binding proteins of bacterial cell wall.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against both gram-positive and gram-negative bacteria. High resistance to most bacterial beta-lactamases. Do not
         use to treat methicillin-resistant <i>Staphylococci</i> (MRSA).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Complicated appendicitis and peritonitis, bacterial meningitis caused by susceptible bacteria, complicated skin infections.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Other intraabdominal infections, skin/soft tissue infections, febrile neutropenia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to meropenem, other carbapenem antibiotics including imipenem, penicillins, cephalosporins, or other beta-lactams;
         lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of asthma or allergies, renal impairment, epileptics, history of neurologic disorders, older adult, pregnancy (category
         B). Safety and effectiveness in infants 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Intraabdominal Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1 g q8h<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> <img src="../images/special/greaterorequal.gif"/><i>3 mo,</i> 20 mg/kg q8h (max: 1 g q8h)<br/><br/><span class="indicationtitle">Bacterial Meningitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 2 g q8h<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> <img src="../images/special/greaterorequal.gif"/><i>3 mo,</i> 40 mg/kg q8h (max: 2 g q8h)<br/><br/><span class="indicationtitle">Complicated Skin Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 500 mg q8h<br/><span class="rdage">Child (&gt;3 mo):</span> <span class="rdroute">IV</span>  10 mg/kg q8h (max: 500 mg q8h)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 2650 mL/min: 1 g q12h; 1025 mL/min: 500 mg q12h; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Dosage reduction is recommended for older adults.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute the 500-mg or 1-g vial, respectively, by adding 10 or 20 mL sterile water for injection to yield approximately
                  50 mg/mL. Shake to dissolve and let stand until clear.  <span class="methodtype">IV Infusion:</span> Further dilute in 50100 mL of D5W, NS, or D5/NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 35 min.  <span class="methodtype">IV Infusion:</span> Give over 1530 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Ringer's lactate,</b>
<b>mannitol,</b>
<b>amphotericin B,</b>
<b>metronidazole,</b>
<b>multivitamins.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B,</b>
<b>diazepam,</b>
<b>metronidazole.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store undiluted at 15°30° C (59°86° F), diluted IV solutions should generally be used within
            1 h of preparation.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Diarrhea, nausea, vomiting, constipation. <span class="typehead">Other:</span> Inflammation at injection site, phlebitis, thrombophlebitis. <span class="typehead">CNS:</span> Headache. <span class="typehead">Skin:</span> Rash, pruritus, diaper rash. <span class="typehead">Body as a Whole:</span> Apnea, oral moniliasis, sepsis, shock. <span class="typehead">Hematologic:</span> Anemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> will delay meropenem excretion; may decrease <b>valproic acid</b> serum levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Attains high concentrations in bile, bronchial secretions, cerebrospinal fluid. <span class="typehead">Metabolism:</span> Undergoes renal and extrarenal metabolism via dipeptidases or nonspecific degradation. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 0.81 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform C&amp;S tests prior to therapy. Monitor periodically liver and kidney function.</li>
<li>Determine history of hypersensitivity reactions to other beta-lactams, cephalosporins, penicillins, or other drugs.</li>
<li>Discontinue drug and immediately report S&amp;S of hypersensitivity (see Appendix F).</li>
<li>Report S&amp;S of superinfection or pseudomembranous colitis (see Appendix F).</li>
<li>Monitor for seizures especially in older adults and those with renal insufficiency.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn S&amp;S of hypersensitivity, superinfection, and pseudomembranous colitis; report any of these to physician promptly.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>